Publicaciones en colaboración con investigadores/as de Hospital Infanta Leonor (98)

2024

  1. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

  2. Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism

    Frontiers in Endocrinology, Vol. 15

  3. Epidemiology of fungal infection in COVID 19 in Spain during 2020 and 2021: a nationwide study

    Scientific Reports, Vol. 14, Núm. 1

  4. Executive summary of the consensus document for the training and development of clinical ultrasound in internal medicine: Recommendations from the Clinical Ultrasound Working Group of the Spanish Society of Internal Medicine (GTECO-SEMI)

    Revista Clinica Espanola, Vol. 224, Núm. 1, pp. 57-63

  5. Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register

    Endocrine, Vol. 84, Núm. 2, pp. 683-693

  6. Multidisciplinary Delphi consensus on challenges and key factors for an optimal care model in chronic kidney disease

    Nefrologia

  7. Real-life data of immune recovery using bictegravir/emtricitabine/ tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 3, pp. 595-607

  8. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry

    High Blood Pressure and Cardiovascular Prevention, Vol. 31, Núm. 1, pp. 43-53

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes

    Endocrine Connections, Vol. 12, Núm. 9

  3. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  4. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

    Viruses, Vol. 15, Núm. 2

  5. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study

    The Lancet Microbe, Vol. 4, Núm. 6, pp. e431-e441

  6. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

    Viruses, Vol. 15, Núm. 4

  7. Epidemiology of Fabry disease in patients in hemodialysis in the Madrid community

    Nefrologia, Vol. 43, Núm. 4, pp. 435-441

  8. Epidemiology of bacterial co-infections and risk factors in COVID-19-hospitalized patients in Spain: a nationwide study

    European journal of public health, Vol. 33, Núm. 4, pp. 675-681

  9. Impact of congestion and perfusion status in the emergency department on severity of decompensation and short-term prognosis in patients with acute heart failure

    European Heart Journal: Acute Cardiovascular Care, Vol. 12, Núm. 3, pp. 165-174

  10. Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry

    European Journal of Clinical Pharmacology, Vol. 79, Núm. 10, pp. 1333-1339

  11. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  12. Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)

    Journal of Clinical Medicine, Vol. 12, Núm. 3